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This study aimed to determine whether absolute sex hormone concentrations predict the 
magnitude of knee joint laxity changes across the menstrual cycle. Twenty-two females (18–30 
years, body mass index ≤30), who reported normal menstrual cycles for the previous 6 months 
were tested daily across one complete menstrual cycle for serum levels of estradiol (E = pg/mL), 
progesterone (P = ng/mL), and testosterone (T = ng/dL), and knee joint laxity (KLax = mm 
displacement at 134N) measured with a standard knee arthrometer. The change in KLax across the 
cycle (maximum–minimum), and minimum (early follicular) and peak (postovulatory) hormone 
concentrations were recorded for each subject. A stepwise linear regression determined if the 
minimum, peak, or absolute change in hormone concentrations would predict the magnitude of 
change in KLax across the cycle. KLax changed on average 3.2 ± 1.1 mm across the menstrual 
cycle (range, 1.5–5.3 mm). Minimum levels of E (39.9 ±11.8 pg/mL) and P (0.61 ± 0.27 ng/mL), 
coupled with peak concentrations of E (199.6 ± 54.9 pg/mL) and T (22.5 ± 10.5 ng/dL) 
explained 57.6% of the change in KLax across the cycle. Greater absolutechanges in KLax were 
observed in response to peak E and T levels when minimum E concentrations were lower and 
minimum P concentrations were higher in the early follicular phase. The absolute minimum 
concentrations of E and P in the early follicular phase appear to be important factors in 




Anterior knee laxity changes across the menstrual cycle,1–3 and these changes are largely 
dependent on changes in sex hormone concentrations.4 We have found that significant increases 
in knee laxity occurred between the early follicular phase and early luteal phase, and that 
estradiol, progesterone, testosterone, and their interactions explained on average ~63% of the 
change in knee laxity across the cycle when a time delay (~3–4 days) was considered.3,4 
However, the length of the time delay (from when hormone levels change to when knee laxity 
changes), the relative contribution of each hormone to the variance explained, and the amount of 
knee laxity change (~1–5 mm) that occurs across the cycle varied widely between subjects. 
Because these knee laxity changes are fairly transient,3 this variability makes it difficult to 
identify a specific day or range of days to represent the same point in the cycle for all females, 
and requires almost daily tracking to know when and if a particular female will experience 
significant knee laxity changes from month to month. This variability may also explain why 
some studies have failed to show cyclic changes in knee laxity across the menstrual cycle based 
on a single, representative test day for each phase.5,6 While this intersubject variability creates 
challenges both for the clinician and researcher, it is consistent with the variability in hormone 
profiles between females.7 
 
It is well known that sex hormone levels, particularly estrogen and progesterone, fluctuate across 
the menstrual cycle and vary by phase. Although rarely considered when describing the female 
menstrual cycle, testosterone concentrations also vary across the cycle, typically peaking during 
the middle third of the cycle.8,9 These cyclic variations in estrogen, progesterone, and 
testosterone can be quite different between individual females in regards to cycle length (both 
follicular and luteal phases), hormone phasing, day of ovulation, and absolute changes in 
hormone levels across the cycle.7,10–12 Hence, it is not surprising that if sex hormones play a 
primary role in mediating changes in knee laxity, this variability in hormone profiles might 
explain why some women experience marked changes in knee laxity across the cycle while 
others do not. 
 
In an effort to better understand the hormonal profile that mediates substantial changes in knee 
laxity across the menstrual cycle, our purpose was to determine whether the minimum, peak, or 
the absolute change in hormone levels would explain the intersubject variability in the magnitude 
of knee laxity changes. We hypothesized that the absolute magnitude of change in hormone 




Data for this study were from a larger project on gender, hormones, and knee laxity,3,4 and 
consisted of 22 females [23.0 ± 3.5 years; 163.4 ± 5.6 cm; 65.0 ± 11.6 kg; 24.3 ± 3.5 body mass 
index (BMI); 2.7 ± 2.1 h of physical activity per week), who reported normal menstrual cycles 
(28–32 days) over the previous 6 months. A sample size of 20 subjects was determined a priori 
through pilot analysis, and inclusion criteria were no history of pregnancy, no use of oral 
contraceptives or other hormone-stimulating medications for 6 months, nonsmoking behavior, 
two healthy knees with no prior history of joint injury or surgery, no medical conditions affecting 
the connective tissue (e.g., Marfan’s syndrome, Ehlers–Danlos disease, rheumatoid arthritis, 
etc.), and physical activity limited to 7 h or less per week to reduce the likelihood of irregular or 
anovulatory menstrual cycles that can occur with high volume or high intensity training.13,14 
Participants were excluded if they experienced an anovulatory cycle (ovulation kit did not test 
positive or progesterone levels rose <3 ng/mL15,16) or if they missed 3 or more consecutive days 
of testing during the cycle. Because of the daily data collection needs of this project, a total of 25 
subjects were originally recruited to insure 20 subjects completed the study. Two subjects were 
lost due to exclusionary criteria (one experienced an anovulatory cycle and one lost more than 3 
days of data collection due to an equipment failure), and one subject voluntarily withdrew prior 
to completing the study. All subjects were informed of the study and associated risks, and signed 
an informed consent approved by the University Health System’s Human Investigation 
Committee and General Clinical Research Center’s Research Advisory Committee. 
 
Procedure 
Participants were instructed to begin using a commercially available ovulation kit {CVS One 
Step Ovulation Predictor [sensitivity, 20 mIU/mL luteinizing hormone (LH); accuracy 99%]; 
CVS Corporation, Woonsocket, RI} on day 8 of their menstrual cycle, and were asked to report 
to the research study coordinator the day the test became positive. Day of ovulation was 
confirmed to (1) insure an ovulatory menstrual cycle had occurred; (2) provide a common 
reference point by which to counterbalance participants and to mark the beginning and ending of 
data collection; and (3) provide indirect confirmation that female subjects were not pregnant. 
 
Hormone assays and knee joint testing were performed in the University’s General Clinical 
Research Center. Participants were tested daily across one complete menstrual cycle, undergoing 
the same data collection procedures on each day of testing. Testing was performed in the 
morning (8:00 A.M.–12:00 P.M.) to obtain the most stable concentrations17 and to control for 
diurnal fluctuations in hormone levels.18 Within this window, every attempt was made to bring 
subjects in at the same time each day. However, some flexibility was needed to accommodate 
participant’s class and work schedules given the daily data collection requirements. Participants 
were counterbalanced to begin and end data collection either at ovulation (ovulation kit detecting 
the leutinizing hormone surge), or the onset of menses (self-report of the first day of menstrual 
bleeding). The test examiner was blinded to the participant’s time in the cycle. 
 
On each day of testing, 5–7 cc of venous blood were drawn to assay serum levels of estradiol 
(pg/mL), progesterone (ng/mL), and testosterone (ng/dL). Estradiol was analyzed using a double-
antibody RIA Assay (DSL-4400; Diagnostic Systems Laboratories, Webster, TX). Progesterone 
and testosterone levels were analyzed using chemiluminescence assays (Coat-A-count; 
Diagnostic Products Corporation, Los Angeles, CA). Mean percentage coefficient of variations 
(% CV) ranged from 3.9%–14.1% (intra-assay) and 2.8%–16.3% (interassay) for estradiol, 
3.4%–10.0% (intra-assay) and 3.8%–12.0% (interassay) for progesterone, and 4.5%–11.3% 
(intra-assay) and 5.2%–13.8% (interassay) for testosterone. Assay sensitivities for estradiol, 
progesterone, and testosterone were 1.5 pg/mL, 0.1 ng/mL, and 10 ng/dL, respectively. 
 
Knee laxity was measured as the amount of anterior tibial displacement at 133N with a KT 
2000™ knee arthrometer (MEDmetric® Corp; San Diego, CA). Using manufacturer’s guidelines, 
subjects were positioned in supine with (1) a thigh support placed just proximal to the popliteal 
fossa to support the knees in 25° of flexion, (2) the ankles placed in the manufacturer-provided 
foot cradle, and (3) a Velcro strap placed around the thighs to control rotation of the lower 
extremity. With the KT-2000™ properly positioned on the anterior tibia of the lower extremity 
(side counterbalanced between participants), the participants were instructed to relax the thigh 
muscles, and an anterior-to-posterior directed force was applied to the anterior tibia to identify a 
stable neutral point, followed by an anterior directed force just over 133N. A bubble level was 
affixed to the device to insure a direct, anterior line of pull. Five trials were collected on each test 
day, and the average of the middle three trials was recorded as the participant’s knee laxity 
measure. While a single investigator performed the majority of knee laxity measures throughout 
the study, a second investigator was trained and utilized to perform knee laxity measures when 
the primary tester was unavailable. Excellent intertester and intratester reliability for these 
investigators was established and previously reported.4 
 
Data Analysis 
Hormone concentrations (estradiol, progesterone, testosterone) and anterior knee laxity at 133N 
were recorded for each day of the menstrual cycle. The range in knee laxity values for each 
female was determined by subtracting the minimum from the maximum values obtained across 
their cycle. Minimum and maximum values for estradiol, progesterone, and testosterone were 
also obtained during the early follicular (first 7 days of the cycle when sex hormones are 
generally lowest) and the luteal phase (postovulation), respectively. A stepwise multilinear 
regression was used to determine whether the minimum, maximum, or the absolute change in 
hormone levels from follicular to luteal phases would predict the magnitude of change in knee 
laxity across the cycle. With this procedure, the hormone variable with the highest correlation 
with knee laxity change was entered first, followed by the next hormone variable with the 
highest significant partial correlation with knee laxity change once the effects of the previous 
variable was accounted for. We continued this process until the addition of further variables did 
not significantly improve the prediction equation. This process maximized the prediction 
accuracy with the smallest number of predictors, and insured that all variables entered in the 
model were significant contributors to the model. 
 
RESULTS 
Table 1 provides the descriptive statistics for knee laxity change and minimum and maximum 
serum estradiol, progesterone, and testosterone levels. All minimum and peak hormone 
concentrations were within normal ranges.19 Tables 2 and and33 list the Pearson (bivariate, zero-
order) correlations and the regression model summary results, respectively, from the stepwise 
regression analysis. Minimum levels of estradiol (Estmin) and progesterone (Progmin) during the 
follicular phase and peak levels of estradiol (Estpeak) and testosterone (Testpeak) each contributed 
significantly to the regression model and collectively accounted for 57.6% of the variance in 
knee laxity change across the menstrual cycle (Table 3). In the stepwise regression, the Progmin 
entered the model first with the highest zero-order correlation with knee laxity change (0.491), 
explaining 20% of the variance in the knee laxity change across the cycle. Once Progmin was 
accounted for, Estpeak had the highest partial correlation (rpartial = 0.535) with knee laxity change 
and entered the model next, followed by Estmin (rpartial = −0.422), which together explained an 
additional 27.7% of the variance. Testpeak (rpartial = 0.479) was the last to enter, and increased the 
variance explained by another 9.5% (Table 3). Testmin and Progpeak did not contribute 
significantly to the regression model and were therefore excluded. The regression equation for 
the four predictor model is as follows: 
 
Table 1: Means ± Standard Deviation and Range for Minimum and Peak Estradiol, 
Progesterone, and Testosterone Levels, and Knee Laxity Change across the Menstrual Cycle    
(N = 22) 
 Means ± SD Range 
EstMin (pg/mL) 39.91 ± 11.82 23.30–57.50 
ProgMin  (ng/mL) 0.61 ± 0.27 0.30–1.10 
TestMin  (ng/dL) 22.50 ± 10.49 10.00–48.00 
EstPeak (pg/mL) 203.02 ± 53.60 85.57–295.00 
ProgPeak (ng/mL) 12.32 ± 4.30 4.70–20.70 
TestPeak (ng/dL) 66.00 ± 6.56 37.00–115.0 
Knee Laxity Change (mm) 3.19 ± 1.09 1.51–5.31 
Min, minimum concentration; Peak, peak concentration; Est, estradiol; Prog, progesterone; Test, testosterone. 
 
 
Table 2: Pearson Correlations for Variables Entered in the Stepwise Regression Model 
 Knee LaxityChange EstMin ProgMin TestMin EstPeak ProgPeak TestPeak 
Knee LaxityChange 1.000 −0.428* 0.491* 0.004 −0.005 −0.078 0.326 
EstMin  1.000 −0.068 0.345 −0.093 0.190 0.282 
ProgMin   1.000 0.092 −0.693* −0.043 0.011 
TestMin    1.000 0.155 0.114 0.293 
EstPeak     1.000 0.030 0.223 
ProgPeak      1.000 0.108 
TestPeak       1.000 
Min, minimum concentration; Peak, peak concentration; Est, estradiol; Prog, progesterone; Test, testosterone. *P ≤ 0.05. 
 
Table 3: Stepwise Regression Model Summary 
     Change Statistics 
Model R R2 Adjusted R2 Standard Error of the Estimate R2 Change F Change df1 df2 Significant F Change 
1 0.491 0.242 0.204 0.969 0.242 6.369 1 20 0.020 
2 0.677 0.459 0.402 0.840 0.217 7.618 1 19 0.012 
3 0.745 0.555 0.481 0.782 0.096 3.896 1 18 0.064 
4 0.811 0.657 0.576 0.707 0.102 5.054 1 17 0.038 
Min, minimum concentration; Peak, peak concentration; Est, estradiol; Prog, progesterone; Test, testosterone. 
11Predictors: (Constant), ProgMin . 
22Predictors: (Constant), ProgMin , EstPeak. 
33Predictors: (Constant), ProgMin , EstPeak, EstMin. 





Examination of the regression coefficients revealed that when minimum progesterone 
concentrations were higher and minimum estradiol concentrations were lower during the early 
follicular phase, females experienced greater increases in knee laxity across the menstrual cycle 
with attainment of peak estradiol and testosterone levels postovulation. While the zero-order 
correlation showed no relationship between peak estradiol concentrations and knee laxity change 
values (Table 2; r = −0.005), their partial correlation increased considerably (rpartial = 0.535), 
once minimum progesterone concentrations were accounted for. 
 
DISCUSSION 
Our earlier report indicated that sex hormones explain, on average, 63% of the change in knee 
laxity across the menstrual cycle within individual females.4 However, we could not determine 
from these data why some females experienced marked changes in knee laxity while others did 
not. Because females varied considerably in their nadir and peak hormone concentrations, we 
sought to determine in the current analysis the extent to which these concentrations may predict 
the magnitude of knee laxity change each female experienced. Our primary findings revealed 
that when progesterone levels were higher and estrogen levels were lower during the early 
follicular phase (i.e., a more androgenic environment), females experienced a greater increase in 
knee laxity once estrogen and testosterone levels peaked. Although simple bivariate correlations 
revealed no relationship between peak estradiol levels and knee laxity change, the relationship 
between these variables was much stronger once minimum progesterone levels were accounted 
for. These findings suggest that the absolute minimum concentrations of estradiol and 
progesterone in the early follicular phase play an important role in determining the threshold of 
the knee joint’s sensitivity to rising estrogen and testosterone levels. Because both absolute 
minimum and maximum values were found to play a significant role in predicting knee laxity 
changes, we believe our hypothesis was in large part supported. 
 
Pulsatile secretion is characteristic of many hormones, and is critical to the triggering of 
hormone-dependent responses to target cells.19,20 For example, a fall in plasma estradiol is 
necessary to trigger normal menstrual cycle events, specifically the rise in follicle stimulating 
hormone (FSH) that initiates follicular recruitment at the beginning of the menstrual cycle.10,19 In 
the case of growth hormone, continuous versus intermittent presence of growth hormone dictates 
the responsiveness of tissues and, ultimately, their sex-differentiated gene expression and growth 
characteristics.20 The effects of parathyroid hormone are also dependent on dose and duration of 
exposure. Continuous treatment with parathyroid hormone increases mRNA for differentiation of 
osteoclasts that increases bone absorption, while intermittent treatment with parathyroid 
hormone increases the production of osteoblasts, leading to bone accumulation.21 
 
A tissue-dependent response to hormone pulsatility has also been demonstrated in human 
anterior cruciate ligament fibroblasts in vitro. Yu and colleagues22 noted that type I procollagen 
synthesis decreased in a dose-dependent manner with increasing estradiol concentrations. 
However, this response was most pronounced in early periods of estradiol exposure (days 1 and 
3), then began to attenuate within 7 days of exposure. This attenuation was thought to either be 
due to a saturation of the estrogen receptors, or perhaps a downregulation of the receptor 
response with prolonged exposure.22 While the literature supports the presence of estrogen and 
progesterone receptors in the human anterior cruciate ligament (ACL)23 and that sex hormones 
may have a direct influence on collagen tissue,24–28 the results by Yu and colleagues suggest the 
degree of pulsatility of these hormones can modify the response by the receptors and influence 
collagen structure and metabolism. 
 
In the present study, higher estrogen and lower progesterone levels during menses were related 
to a greater stability in knee laxity values across the menstrual cycle. Based on the 
aforementioned examples of hormone pulsatility effects, nadir estrogen levels may stay 
sufficiently high during the early follicular phase in some females so as to “dampen” the 
collagen receptors response to rising estradiol and testosterone levels, resulting in no substantial 
change in ligament behavior. Conversely, those females who experienced a more androgenic 
profile (lower estradiol, higher progesterone) experienced a marked increase in joint laxity 
following peak ovulatory levels. While it is difficult to compare these results with other studies, 
it is interesting to note that in two studies that did not identify changes in knee laxity across 
select days of the menstrual cycle,5,6 average estradiol levels were near the upper limits of 
normal ranges at menses (56 and 73 pg/mL) and considerably below the normal ranges 
postovulation (137 and 120 pg/mL) using similar hormone assays. Hence, their results would 
actually be consistent with our current findings of little or no change in knee laxity in subjects 
who maintain higher nadir and lower peak estradiol levels. However, because the values reported 
were only sampled on a single representative day for each phase, one cannot be sure whether 
they truly represent peak and nadir values, or whether other factors explain the lack of cyclic 
knee laxity changes observed.5 
 
In contrast to our earlier findings that did not identify a clear relationship between changes in 
progesterone concentrations and knee laxity changes,4 the current analyses appear to indicate that 
nadir progesterone concentrations may be a primary mediator of changes in knee laxity. The 
bivariate correlations between progesterone and knee laxity change was moderately high (r = 
0.491), and was the first variable to enter the regression model, explaining 20% of the variance 
in knee laxity alone. Once minimum progesterone levels were accounted for, peak and minimum 
estradiol levels explained an additional 28% of the variance in knee laxity. It is important to note, 
however, that exploratory regression analyses revealed that peak estradiol concentrations would 
not have entered the model without first accounting for minimum progesterone levels, but 
minimum estradiol levels would have still entered and independently explained 14% of the 
variance. These findings suggest that the sensitivity of the knee joint to greater absolute changes 
in estradiol levels from the early follicular to early luteal phase is largely dependent on the nadir 
levels of estradiol and progesterone. This would appear to be consistent with basic science 
studies that have demonstrated an interactive effect between estradiol and progesterone in 
modifying collagen structure.24,27 Romani and colleagues29 also found stronger correlations 
between ACL stiffness and estradiol concentrations once the effects of other hormones were 
accounted for. 
 
The additional contribution of testosterone to the equation is less clear. Although concentrations 
of testosterone are substantially lower in females (<100 ng/dL) than males (300–1000 ng/dL), the 
ovaries secrete testosterone during the course of the menstrual cycle,19 and these concentrations 
can increase as much as two- to threefold around the LH surge midcycle.8,9,19 We chose to 
include testosterone in the current analysis because these values also vary considerably between 
females as well as within females across their cycle (see Table 1), and our earlier work indicated 
a positive relationship between testosterone and changes in knee laxity that were independent of 
the effects of estrogen and progesterone.4 This positive relationship was upheld in the current 
analysis, with peak testosterone concentrations accounting for an additional 10% of the variance 
in knee laxity change. However, minimum testosterone levels did not contribute to knee laxity 
changes, suggesting there is no specific minimum threshold on which the effects of testosterone 
are dependent. Of interest, these relationships remained unchanged when estrogen and 
progesterone were excluded from the model. The physiological importance of the positive 
relationship between peak testosterone concentrations and knee laxity change is currently 
unknown, and is difficult to speculate based on previous findings. While Hamlet and 
colleagues30 identified androgen receptors on the human ACL in young adult males, they did not 
observe the presence of these receptors in females. Further, the effects of testosterone on 
collagen tissue have consistently been found to be anabolic in nature, increasing collagen content 
and fiber diameter24,27 and decreasing elastin content.31 This would suggest testosterone would 
have more of a stiffening effect on the capsuloligamentous structures, rather than contributing to 
increased knee laxity as we observed. Further research is needed to understand the physiological 
importance of rising testosterone levels in mediating changes in knee laxity. 
 
Clinical Relevance 
Mounting evidence suggests that sex differences in knee laxity are largely dependent on sex 
hormone concentrations and are greatest when females are in the early luteal phase of their 
menstrual cycle.1–4 In some females, these changes in knee laxity exceed 3 mm, an amount that 
is considered to be diagnostic of ACL injury,32 while other females experience relatively little 
variations in knee laxity across the cycle. This variable knee laxity response among females may 
be an important risk factor consideration, as recent epidemiology suggests that increased knee 
laxity is a relevant factor in predicting ACL injury risk in females,37 and has the potential to alter 
the passive restraints, articular surface congruity and contact, and active muscle forces that 
contribute to knee stability.33–36 Therefore, understanding those factors that can modify knee 
laxity, and being able to identify which females may experience significant changes in knee 
laxity as a result of these factors would have clinical value. 
 
The current study identified that minimum concentrations of estrogen and progesterone during 
days of menses are critical factors in predicting the magnitude of knee laxity increase with rising 
estrogen and testosterone levels. These findings further clarify the complex, variable 
relationships between sex hormones and changes in knee laxity that we previously reported 
among individual females.4 Confirmation of the current findings would be clinically beneficial in 
that it would greatly simplify methods for identifying females as “hormone responders” 
(experiencing transient changes in knee laxity across the cycle) or “hormone non-responders” 
(knee laxity remaining fairly stable across the cycle), should transient changes in knee laxity 
represent a variable injury risk factor among women. Obtaining measures during the menstrual 
phase and for 2–3 days following ovulation (when estrogen is known to peak) may be sufficient 
to identify clinically important changes in knee laxity, without having to track females across 
their entire cycle. These findings may also be valuable to researchers and clinicians when 
examining knee laxity over time (e.g., monitoring joint laxity following ACL reconstruction), 
depending on the time in the cycle when these measures are taken. Work is ongoing to further 
characterize the hormone profile that produces increased knee laxity in females, and determine 
the extent to which both absolute and transient increases in knee laxity impact weight bearing 
knee joint neuromechanics and injury risk. 
 
Limitations 
While our study represents an initial step in describing hormone profile(s) that dictate knee laxity 
changes in women, our findings are limited to a relatively small sample size and measurements 
obtained over a single cycle. In our regression model, we used six predictors with a sample size 
of 22, which has the potential to inflate the correlations. Generally, 10 subjects per predictor (in 
this case, 60 subjects) are recommended. However, had we examined minimum versus 
maximum hormone concentrations separately, we would not have identified the interdependency 
between the two. To address this concern and provide a more accurate reflection of the strength 
of the regression, we reported the more conservative adjusted R2 value to account for the 
percentage of variance that may be due to chance.38 Even with this conservative approach, we 
believe it is important to confirm these findings in a larger sample in future studies. It is also not 
known from these data whether females will experience consistent changes in knee laxity from 
month to month. Females do vary somewhat in their cycle from month to month (although 
substantially less than the variability between females),39 so this variability should also be 
explored in future work. While the ideal study may involve direct control and manipulation of 
the subject’s sex steroids by a GnRH antagonist, the risk–benefit ratio with the currently 
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